Previous 10 | Next 10 |
Replimune's (REPL) on lead programs, RP1 and RP2, demonstrated anti-tumor activity and robust immune response in clinical biomarker studies, according to new preclinical data.The data, presented at the American Association for Clinical Oncology meeting, showed that RP1 in combination with Opd...
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2 Increased infiltration of CD8+ T cells and PD-L1 expression for patients dosed with RP1 in combination with Opdivo ® (nivolumab) and single agent RP2 i...
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced two poster presentations at the upcoming American Association for Cancer Re...
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-o...
WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will presen...
Replimune Group (REPL): FQ3 GAAP EPS of -$0.44 misses by $0.03.Cash, equivalents and short-term investments were $493.3M, as compared to $168.6M as of March 31, 2020.Press Release For further details see: Replimune Group EPS misses by $0.03
The following slide deck was published by Replimune Group, Inc. in conjunction with this event. For further details see: Replimune (REPL) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies RP2; New data to be reported in 2021 in combination with Opdivo in Phase 1 ...
WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will presen...
Replimune ([[REPL]] +1.2%) has dosed the first patient in a Phase 1, open-label, dose-escalation and expansion clinical trial of gene therapy RP3 both alone and in combination with anti-PD-1 therapy, for advanced solid tumors.The immune-gene therapy to treat advanced solid tumors is...
News, Short Squeeze, Breakout and More Instantly...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...
2024-06-07 07:00:05 ET Robert Burns from H.C. Wainwright issued a price target of $17.00 for REPL on 2024-06-07 06:07:00. The adjusted price target was set to $17.00. At the time of the announcement, REPL was trading at $7.11. The overall price target consensus is at $26...